H.C. Wainwright raised the firm’s price target on Purple Biotech to $9 from $7 and keeps a Buy rating on the shares post the Q2 report. The company’s CEO Gil Efron has returned from medical leave and the firm confirmed that there have been no delays in clinical development. All of Purple’s timelines remain on track, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PPBT:
- Purple Biotech Reports Second Quarter 2023 Financial Results
- Purple Biotech reports Q2 EPS (25c), consenus (26c)
- Purple Biotech initiated with a Buy at JonesResearch
- Purple Biotech reports results of CM24 dose escalation
- Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients